Wewnątrzsercowe urządzenia wszczepialne w niewydolności serca

Abstract

With widespread access to intracardiac implantable devices, the number of people with heart failure (HF) who underwent primary or secondary prophylaxis has increased. Technological progress has made it possible to construct modern high-energy intracardiac devices, allowing them to achieve the intended therapeutic goals. However, it should be considered that implantation of the device may be associated with complications, the frequency of which varies depending on the experience of the operator, the age of the patient, the degree of multi-organ failure and the patient’s coexisting conditions. Implantation of cardioverter-defibrillator or cardiac resynchronisation therapy, in a properly qualified patient and experienced team of interventional cardiologists, is associated with the risk of a relatively low percentage of early and distant complications. An important element of patient management is striving to eliminate inadequate interventions that adversely affect both the patient’s functioning and quality of life. It is important to educate the patient, as well as highlight the risks associated with alcohol and medication abuse, illegal sports and non-compliance with pharmacotherapy recommendations. Optimal pharmacological treatment of HF and co-existing diseases and systematic control of the device during visits to the clinic or using remote monitoring is necessary.